Dermata Therapeutics(DRMA.US)

Last Updated 19:00:00 ET
longbridge loading

Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4

Tip Ranks·
US
DRMA
-1.69%
US
DRMAW
0.00%
US
BBH
+0.33%
Tip Ranks·
US
DRMA
-1.69%
US
DRMAW
0.00%
US
BBH
+0.33%

Dermata Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
DRMA
-1.69%
Earnings Watch·
US
DRMA
-1.69%

Dermata Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
DRMA
-1.69%
Earnings Watch·
US
DRMA
-1.69%

Dermapharm Holding SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements

EQS·
US
DRMAW
0.00%
US
DRMA
-1.69%
EQS·
US
DRMAW
0.00%
US
DRMA
-1.69%

Veradermics Announces Pricing of Upsized Public Offering and Private Placement | MANE Stock News

StockTitan·
US
DRMA
-1.69%
US
DRMAW
0.00%
US
IBB
+1.75%
StockTitan·
US
DRMA
-1.69%
US
DRMAW
0.00%
US
IBB
+1.75%

Galderma Posts Q1 Sales Growth, Confirms FY26 Outlook, Stock Up

rttnews·
US
DRMA
-1.69%
US
IHE
+0.77%
US
XBI
+2.82%
rttnews·
US
DRMA
-1.69%
US
IHE
+0.77%
US
XBI
+2.82%

Global Keloid Treatment Market Outlook | North America, Asia Pacific, Europe Lead | Bausch Health, Sciton, Galderma Drive Multi-Modal Dermatology Innovation

MorningStar·
US
DRMAW
0.00%
US
DRMA
-1.69%
US
GRTX
0.00%
MorningStar·
US
DRMAW
0.00%
US
DRMA
-1.69%
US
GRTX
0.00%

Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra® and Restylane® in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause

MorningStar·
US
FBT
+0.76%
US
BBH
+0.33%
US
VHT
+0.55%
MorningStar·
US
FBT
+0.76%
US
BBH
+0.33%
US
VHT
+0.55%

Dermata Therapeutics | 10-K: FY2025 Revenue: USD 0

Earnings Watch·
US
DRMA
-1.69%
Earnings Watch·
US
DRMA
-1.69%

Dermata Therapeutics | 8-K: FY2025 Revenue: USD 0

Earnings Watch·
US
DRMA
-1.69%
Earnings Watch·
US
DRMA
-1.69%
© 2026 Longbridge｜Disclaimer